Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma
A technology of beclomethasone dipropionate and formoterol, applied in the field of prevention and/or treatment of exacerbation of asthma, intermittent asthma and/or acute exacerbation of chronic asthma, which can solve the problems of poor patient compliance, inadequate treatment, quality of life Effects and other issues, achieve the effect of reducing bronchoconstriction and improving usability
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
Embodiment 1
[0052] The pressurized metered-dose inhaler solution formulation of the combination formoterol fumarate + beclomethasone dipropionate contains formoterol fumarate dihydrate 6 μg / dose (0.010% w / w, based on the total weight), beclomethasone dipropionate 100 μg / dose (0.172% w / w), ethanol 12% w / w (as a co-solvent) and hydrochloric acid (1M) 0.024% w / w (as a stabilizer), and used as The HFA 134a of the propellant is made up to 100%. The formulations were packaged in aluminum cans equipped with 50 microliter valves.
Embodiment 2
[0054] The pressurized metered-dose inhaler solution formulation of the combination formoterol fumarate + beclomethasone dipropionate contains formoterol fumarate dihydrate 6 μg / dose (0.008% w / w, based on the total volume of the formulation). weight), beclomethasone dipropionate 200 μg / dose (0.271% w / w), ethanol 12% w / w (as co-solvent) and hydrochloric acid (1M) 0.019% w / w (as stabilizer) and used as propellant The HFA 134a of the agent was supplemented to 100%. The formulations were packaged in aluminum cans fitted with 63 microliter valves.
Embodiment 3
[0056] The dry powder inhaler formulation of the combination formoterol fumarate + beclomethasone dipropionate contains micronized formoterol fumarate dihydrate 6 μg / dose (0.06% w / w, based on the total weight of the formulation ), micronized beclomethasone dipropionate 100 μg / dose (1% w / w), 989 μg / dose premixed mixture (9.89% w / w) (composed of 98:2 w / w micronized lactose and magnesium stearate), 8904 μg / dose of coarse alpha-lactose monohydrate (89.04% w / w) with a particle size of 212-355 μm.
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com